Investigators Testing Ways To Overcome Gleevec Resistance: High Dose, New Drugs
FDA Approves Abraxane For Second-Line Treatment Of Metastatic Breast Cancer
New Regimens May Benefit Multiple Myeloma Patients
Two New Modalities Promising For Relapsed/Refractory NHL
Amgen’s Kepivance Approved For Severe Oral Mucositis
Clolar Approved for Pediatric Refractory/Relapsed ALL
Blacks Half As Likely To Get Surgery For Esophageal Cancer
NCI-Approved Clinical Trials Listed For January
Trending Stories
- U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access - How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute
- Proposed rule by CMS would expand access to cancer treatment at tribal facilities
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence